Tuesday, December 28, 2010
about 13% breast pain in one breast as Symptoms of early breast cancer | Curative
about 13% breast pain in one breast as Symptoms of early breast cancer | Curative
Wednesday, December 15, 2010
Acquired defects in the FGFR1 gene could play a role in lung cancer
An overproduced receptor protein that shows up in a subset of lung cancers may offer a target of opportunity for new drugs and a glimmer of hope for some patients, researchers report.
Excess amounts of a protein known as FGFR1, or fibroid growth factor receptor 1, often show up in smokers who develop a hard-to-treat form of lung cancer, suggesting that tobacco smoke exposure damages the gene encoding this protein and steers cells toward cancer in some people. Researchers report the findings in the Dec. 15 Science Translational Medicine.
Acquired defects in the FGFR1 gene could play a role in lung cancer
Scientists have been investigating the four known FGFR genes for years, and defects in these genes have been linked to cancer of the lung, bladder, uterus, breast and blood, says Lynn Heasley, a physician and researcher at the University of Colorado Denver Anschutz Medical Campus in Aurora who wasn’t part of this study. “This is the first paper where you actually see amplification of the gene in primary [lung] tumors. In that way, it’s an important advance.”
Acquired defects in the FGFR1 gene could play a role in lung cancer
In gene amplification, multiple copies of a defective gene appear and the gene’s protein is overproduced, altering its effect on the cell’s processes. Several research groups have plans to test drugs that inhibit FGFR proteins in cancer patients whose tumors have the gene amplification.
In the new study, the researchers concentrated on squamous cell carcinoma of the lung, a deadly malignancy responsible for about one-fourth of lung cancers. It mainly hits smokers. Analysis of squamous cell tumors from 155 lung cancer patients showed that 15 had a defective FGFR1 gene. Of those 15 patients, 11 were current or former smokers, and data were unavailable for the other four.
The researchers then used a different technique to analyze samples of 153 other squamous cell lung tumors and found that the FGFR1 gene was amped up in 22 percent of them. But the defect turned up in only 1 percent of 581 nonsquamous cell lung tumors included in a publicly available database.
The scientists also tested an FGFR-inhibiting compound called PD173074 against 83 lung cancer cell lines. The compound blocked growth and caused cancer cell death in four of the cell lines, and three of those had an altered FGFR1 gene. When the scientists tested the compound on mice with squamous cell lung cancer, the animals whose tumors had a defective FGFR1 gene benefited from the treatment, showing marked tumor shrinkage.
The compound used in this study is unstable and probably won’t be suitable for people, says study coauthor Roman Thomas, physician and researcher at the Max Planck Institute for Neurological Research and the University of Cologne in Germany. But drug manufacturers, including Novartis and AstraZeneca, have developed other FGFR inhibitors aimed at treating patients.
Early-stage clinical trials of those FGFR inhibitors are recruiting breast cancer patients. Thomas and his colleagues are planning to test an FGFR inhibitor in lung cancer patients who screen positive for the altered FGFR1 gene.
“We’re still in the early days here,” Heasley says, but FGFR inhibitors might hold potential as drugs that can be aimed at tumors that arise in smokers.
Lung cancer takes the largest toll of all malignancies, killing more people than breast, prostate and colon cancer combined. While often treatable when it appears in nonsmokers, fewer options are available for squamous cell lung cancer and other forms that are more common among smokers.
ARTICLE FROM: http://www.sciencenews.org/view/generic/id/67639/title/Gene_linked_to_some_smokers%E2%80%99_lung_cancer
Excess amounts of a protein known as FGFR1, or fibroid growth factor receptor 1, often show up in smokers who develop a hard-to-treat form of lung cancer, suggesting that tobacco smoke exposure damages the gene encoding this protein and steers cells toward cancer in some people. Researchers report the findings in the Dec. 15 Science Translational Medicine.
Acquired defects in the FGFR1 gene could play a role in lung cancer
Scientists have been investigating the four known FGFR genes for years, and defects in these genes have been linked to cancer of the lung, bladder, uterus, breast and blood, says Lynn Heasley, a physician and researcher at the University of Colorado Denver Anschutz Medical Campus in Aurora who wasn’t part of this study. “This is the first paper where you actually see amplification of the gene in primary [lung] tumors. In that way, it’s an important advance.”
Acquired defects in the FGFR1 gene could play a role in lung cancer
In gene amplification, multiple copies of a defective gene appear and the gene’s protein is overproduced, altering its effect on the cell’s processes. Several research groups have plans to test drugs that inhibit FGFR proteins in cancer patients whose tumors have the gene amplification.
In the new study, the researchers concentrated on squamous cell carcinoma of the lung, a deadly malignancy responsible for about one-fourth of lung cancers. It mainly hits smokers. Analysis of squamous cell tumors from 155 lung cancer patients showed that 15 had a defective FGFR1 gene. Of those 15 patients, 11 were current or former smokers, and data were unavailable for the other four.
The researchers then used a different technique to analyze samples of 153 other squamous cell lung tumors and found that the FGFR1 gene was amped up in 22 percent of them. But the defect turned up in only 1 percent of 581 nonsquamous cell lung tumors included in a publicly available database.
The scientists also tested an FGFR-inhibiting compound called PD173074 against 83 lung cancer cell lines. The compound blocked growth and caused cancer cell death in four of the cell lines, and three of those had an altered FGFR1 gene. When the scientists tested the compound on mice with squamous cell lung cancer, the animals whose tumors had a defective FGFR1 gene benefited from the treatment, showing marked tumor shrinkage.
The compound used in this study is unstable and probably won’t be suitable for people, says study coauthor Roman Thomas, physician and researcher at the Max Planck Institute for Neurological Research and the University of Cologne in Germany. But drug manufacturers, including Novartis and AstraZeneca, have developed other FGFR inhibitors aimed at treating patients.
Early-stage clinical trials of those FGFR inhibitors are recruiting breast cancer patients. Thomas and his colleagues are planning to test an FGFR inhibitor in lung cancer patients who screen positive for the altered FGFR1 gene.
“We’re still in the early days here,” Heasley says, but FGFR inhibitors might hold potential as drugs that can be aimed at tumors that arise in smokers.
Lung cancer takes the largest toll of all malignancies, killing more people than breast, prostate and colon cancer combined. While often treatable when it appears in nonsmokers, fewer options are available for squamous cell lung cancer and other forms that are more common among smokers.
ARTICLE FROM: http://www.sciencenews.org/view/generic/id/67639/title/Gene_linked_to_some_smokers%E2%80%99_lung_cancer
Saturday, December 4, 2010
first pregnancy appears to the accumulation of risk, obesity and certain types of breast cancer
In the age of first pregnancy appears to the accumulation of risk, obesity and certain types of breast cancer. A groundbreaking study by University of Wisconsin Medical School and public health leaders said they have children or no life along with obesity, causing the risk of breast cancer. In the conception and the link between age and breast cancer may be strong women who never had children or who waited until 30 or later have a child.
The study consists of about 1912 to 1986 women born in 50000, of which 29,000 were diagnosed with breast cancer. Those aged 30 or over, while the pregnancy first child or a child has never been reported in the elevation of 2.5% of lobular breast cancer. Breast cancer, is clearly the most common form of breast cancer, but the lobular and mixed ductal, lobular breast cancer cases in the 20th century, the rapid increase in 90 years and accounts for 20 percent of all breast cancer events.
"Our study found that children who never or was at or after 30 children had a three times greater development of lobular breast cancer risk in obese women. Has been strong evidence that obesity, sedentary lifestyle and alcohol use can in breast cancer risk factors. These are all risk factors, women can change, "highlighted the cancer center from the Polly Newcomb.
Since lobular breast cancer lobular breast where it started, it may be difficult to find a breast X-rays. Ductal carcinoma, on the other hand, began to pipe lining in a milk and more easy to detect. Authors suggest that postmenopausal hormone replacement and the risk of lobular breast cancer linked.
The study, published in the journal Cancer.
The study consists of about 1912 to 1986 women born in 50000, of which 29,000 were diagnosed with breast cancer. Those aged 30 or over, while the pregnancy first child or a child has never been reported in the elevation of 2.5% of lobular breast cancer. Breast cancer, is clearly the most common form of breast cancer, but the lobular and mixed ductal, lobular breast cancer cases in the 20th century, the rapid increase in 90 years and accounts for 20 percent of all breast cancer events.
"Our study found that children who never or was at or after 30 children had a three times greater development of lobular breast cancer risk in obese women. Has been strong evidence that obesity, sedentary lifestyle and alcohol use can in breast cancer risk factors. These are all risk factors, women can change, "highlighted the cancer center from the Polly Newcomb.
Since lobular breast cancer lobular breast where it started, it may be difficult to find a breast X-rays. Ductal carcinoma, on the other hand, began to pipe lining in a milk and more easy to detect. Authors suggest that postmenopausal hormone replacement and the risk of lobular breast cancer linked.
The study, published in the journal Cancer.
Wednesday, December 1, 2010
Women’s lung cancer rate catching up with men’s
Recently a research shows that women patients with lung cancer dramatic increase in UK, as they fail to heed no-smoking message. Women have been urged to take anti-smoking messages more seriously.
Alexander Ives and Dr Julia Verne, of the NHS’s South West Public Health Observatory, found that: “Lung cancer incidence for females increased significantly from 1985-87 (32.3 per 100,000) to 2004-06 (35.4 per 100,000)”, a 10% rise. While the recent rate for men in England as 60 per 100,000. They said they identify women in England diagnosed with the disease between 1985 and 2006 from data of the UK Association of Cancer Registries.
Traditionally, Lung cancer of male are much more than women, but numbers of women being diagnosed are growing and it become the UK’s biggest cancer killer. The trend now has alarmed us, we should be urging female smokers to quit and calling on the NHS to do more to warn women of the dangerous habit. Women need to take on board that lung cancer is not a disease of men, it’s a disease of smokers, and either not take up smoking in the first place or quit cigarettes as a matter of urgency.
Lung cancer claims more Britons’ lives than any other form of the disease. It is reported that every day about 108 people are diagnosed with it, and of those 95 die. In the 1950s men diagnosed with lung cancer outnumbered women by six to one.
The Office of National Statistics released data last week, it showed that cancers are now the commonest cause of death in women, accounting for 159 deaths per 100,000 annually. It means Scotland has the UK’s highest rates of lung cancer, while cancer generally claims 181 lives per 100,000 women north of the border.
Except smoking, non-smoking cancers is increased too. It’s well known that long-term exposure to tobacco smoke is also the major causes of lung cancer. Air pollution is an other cause.
Alexander Ives and Dr Julia Verne, of the NHS’s South West Public Health Observatory, found that: “Lung cancer incidence for females increased significantly from 1985-87 (32.3 per 100,000) to 2004-06 (35.4 per 100,000)”, a 10% rise. While the recent rate for men in England as 60 per 100,000. They said they identify women in England diagnosed with the disease between 1985 and 2006 from data of the UK Association of Cancer Registries.
Traditionally, Lung cancer of male are much more than women, but numbers of women being diagnosed are growing and it become the UK’s biggest cancer killer. The trend now has alarmed us, we should be urging female smokers to quit and calling on the NHS to do more to warn women of the dangerous habit. Women need to take on board that lung cancer is not a disease of men, it’s a disease of smokers, and either not take up smoking in the first place or quit cigarettes as a matter of urgency.
Lung cancer claims more Britons’ lives than any other form of the disease. It is reported that every day about 108 people are diagnosed with it, and of those 95 die. In the 1950s men diagnosed with lung cancer outnumbered women by six to one.
The Office of National Statistics released data last week, it showed that cancers are now the commonest cause of death in women, accounting for 159 deaths per 100,000 annually. It means Scotland has the UK’s highest rates of lung cancer, while cancer generally claims 181 lives per 100,000 women north of the border.
Except smoking, non-smoking cancers is increased too. It’s well known that long-term exposure to tobacco smoke is also the major causes of lung cancer. Air pollution is an other cause.
Monday, November 29, 2010
booklet to help women with learning disabilities to understand what breast cancer
A booklet towards assistance ladies with knowledge disabilities towards appreciate what breast cancer is and the importance of breast mammography has been launched at the University of Ulster.
Produced via Dr Laurence Taggart, from Ulster’s School of Nursing, ‘My Boobs and Me!’ was styled towards herald breast perception for ladies with knowledge disabilities.
It consumes vocabulary and brightly coloured films towards depict the risk and protective factors of breast cancer, as well as consuming noticeable photos of the ride across hospital within obtaining a mammogram.
In an originally pilot project funded via the Breast Cancer Campaign within 2009, Dr Taggart’s innovation indicated that ladies with knowledge disabilities had complications within experience what breast cancer was and the importance of attending for a mammogram.
“As portion of a team of investigators analysing the women’s experience of breast cancer and breast perception, a lot of these ladies lacked a noticeable experience of what breast cancer was,” he said.
“Also a lot of these ladies did not clearly appreciate the procedure of obtaining a mammogram; these ladies expressed panic and embarrassment. The booklet enables the ladies towards benefit a fuller experience of what beast cancer is, the risk and protective factors, as well recounting the ride across obtaining the invitation letter towards attending for a mammogram within hospital.”
Dr Taggart worked with ladies with knowledge disabilities towards assistance him design the booklet. Compass Advocacy Network, a Ballymoney-based charity, also worked with the Ulster lecturer onto the project. The charity’s ambition is towards enable adults with knowledge disabilities.
“With subsidy knotted from the Breast Cancer Campaign, I caused this booklet. Hopefully it shall assistance ladies with knowledge disabilities towards acknowledge and appreciate the signs and symptoms of breast cancer better and cooperation them within their ride within obtaining the mammogram,” Dr Taggart said.
“The booklet shall also help relations carers, ceremonial carers working with ladies with knowledge disabilities, GP’s, tradition nurses, breast screening nurses, radiographers and else healthcare professionals within backing ladies with knowledge disabilities.”
Copies of the booklet shall be allocated towards everybody the breast screening units across Northern Ireland and the UK, as well as the settlement knowledge disability teams.
Produced via Dr Laurence Taggart, from Ulster’s School of Nursing, ‘My Boobs and Me!’ was styled towards herald breast perception for ladies with knowledge disabilities.
It consumes vocabulary and brightly coloured films towards depict the risk and protective factors of breast cancer, as well as consuming noticeable photos of the ride across hospital within obtaining a mammogram.
In an originally pilot project funded via the Breast Cancer Campaign within 2009, Dr Taggart’s innovation indicated that ladies with knowledge disabilities had complications within experience what breast cancer was and the importance of attending for a mammogram.
“As portion of a team of investigators analysing the women’s experience of breast cancer and breast perception, a lot of these ladies lacked a noticeable experience of what breast cancer was,” he said.
“Also a lot of these ladies did not clearly appreciate the procedure of obtaining a mammogram; these ladies expressed panic and embarrassment. The booklet enables the ladies towards benefit a fuller experience of what beast cancer is, the risk and protective factors, as well recounting the ride across obtaining the invitation letter towards attending for a mammogram within hospital.”
Dr Taggart worked with ladies with knowledge disabilities towards assistance him design the booklet. Compass Advocacy Network, a Ballymoney-based charity, also worked with the Ulster lecturer onto the project. The charity’s ambition is towards enable adults with knowledge disabilities.
“With subsidy knotted from the Breast Cancer Campaign, I caused this booklet. Hopefully it shall assistance ladies with knowledge disabilities towards acknowledge and appreciate the signs and symptoms of breast cancer better and cooperation them within their ride within obtaining the mammogram,” Dr Taggart said.
“The booklet shall also help relations carers, ceremonial carers working with ladies with knowledge disabilities, GP’s, tradition nurses, breast screening nurses, radiographers and else healthcare professionals within backing ladies with knowledge disabilities.”
Copies of the booklet shall be allocated towards everybody the breast screening units across Northern Ireland and the UK, as well as the settlement knowledge disability teams.
Saturday, November 27, 2010
Bone drug cuts breast cancer death rate
A drug designed to treat bone thinning has been found to prevent secondary tumours in women who have had breast cancer and to increase their survival rates.
The study of more than 1,000 women who had received surgery for primary breast cancer found that giving them the drug, bisphosphonate clodronate, for two years reduced the occurrence of bone cancer by 56 per cent.
The number of deaths from the original breast cancers was reduced by 23 per cent. The researchers also detected a trend towards a reduction in cancers of major organs although these findings were not statistically significant.
However, they could be important for other cancers that can lead to cancer in bones, including prostate cancer.
Prof Trevor Powles, head of the breast unit at the Royal Marsden Hospital, London, led the study. He said yesterday: "There were little or few side effects from the treatment.
"So much is now happening in breast cancer that is positive and I am very glad to be involved. Several other studies have already started following our findings."
He said that while the researchers had hoped to see a reduction in the occurrence of cancer of the bones, to which breast cancer commonly spreads, the reduction in the death rate was unexpected.
"The findings of this study are encouraging for breast cancer patients and may pave the way to more routine use of clodrinate or other bisphophonates in the prevention of bone metastases," he said.
Clodrinate, tradename, Bonefos, was first licensed in 1985 to treat bone thinning.
The women in the study, published in the Journal of Clinical Oncology this month, had all had surgery for primary breast cancer which had shown no sign of spreading to their bones. They were also being treated with chemotherapy and tamoxifen.
The study of more than 1,000 women who had received surgery for primary breast cancer found that giving them the drug, bisphosphonate clodronate, for two years reduced the occurrence of bone cancer by 56 per cent.
The number of deaths from the original breast cancers was reduced by 23 per cent. The researchers also detected a trend towards a reduction in cancers of major organs although these findings were not statistically significant.
However, they could be important for other cancers that can lead to cancer in bones, including prostate cancer.
Prof Trevor Powles, head of the breast unit at the Royal Marsden Hospital, London, led the study. He said yesterday: "There were little or few side effects from the treatment.
"So much is now happening in breast cancer that is positive and I am very glad to be involved. Several other studies have already started following our findings."
He said that while the researchers had hoped to see a reduction in the occurrence of cancer of the bones, to which breast cancer commonly spreads, the reduction in the death rate was unexpected.
"The findings of this study are encouraging for breast cancer patients and may pave the way to more routine use of clodrinate or other bisphophonates in the prevention of bone metastases," he said.
Clodrinate, tradename, Bonefos, was first licensed in 1985 to treat bone thinning.
The women in the study, published in the Journal of Clinical Oncology this month, had all had surgery for primary breast cancer which had shown no sign of spreading to their bones. They were also being treated with chemotherapy and tamoxifen.
Tuesday, November 9, 2010
Dutch doctors to kill breast cancer by using ultrasound heating
Carcinoma in situ in patients with early breast cancer after treatment, the cure rate of up to 98%. Licensed psychologists and other mental health professionals with experience in breast cancer treatment can help a great deal. In the early days, the application of radiotherapy in breast cancer treatment was mainly for the recurrent disease after mastectomy or for inoperable disease.
Dutch doctors will try to administer a new treatment to breast cancer patients in December by using ultrasound heating to kill tumor cells, the world’s first attempt of its kind. At present, Chinese scientists are studying the use of proteomics and gene analysis as a means to predict the sensitivity of breast cancer treatment, to develop individualized treatment targets.
Doctors will heat the breast tumors to a temperature of 60 to 90 degrees by using ultrasound technique, tumor cells die off and thus removed from the body, local press quoted sources from University Medical Center(UMC) of Utrecht as saying on Tuesday.
Sunday, November 7, 2010
curative time: chronic constipation may lead to risk of breast ca...
curative time: chronic constipation may lead to risk of breast ca...: "chronic constipation may lead to risk of breast cancerIn recent years, medical workers discovered that not only obesity, diet and genetics w..."
chronic constipation may lead to risk of breast cancer
chronic constipation may lead to risk of breast cancer
In recent years, medical workers discovered that not only obesity, diet and genetics will lead to women suffering from breast cancer，even Long-term chronic constipation Can also cause women to breast cancer.
The medical experts From the University of California has been testing milk and secretions for 1418 women. The results show that Stool once a day, 1 out of 20 women who developed abnormal breast cells, but less than 2 times per week were stool, 4 people will have an abnormal development of human breast cells.
Breast Cancer
Breast Cancer
What is breast cancer?
Breast cancer is the most common malignancy in women in most of countries. According to statistics, the incidence rate in population is 7-10% of various malignant tumors in the body. It’s often hereditary disease. And 40-60 years old, postmenopausal women before and after With a higher prevalence. Only about 1-2% of breast patients were male. It is a malignant tumor，usually begin to come on Glandular tissue in the breast. it is one of the most common malignant tumor, serious impact on women’s health and even life-threatening. Male breast cancer is rare.
Breast Cancer Symptoms
The main symptoms: breast masses, Nipple erosion, breast pain, Nipple Discharge, Axillary lymph nodes. As long as the majority of women can have stronger anti-cancer awareness, Fully understand and master the knowledge, Carefully work out self-examination, With medical care level, Believe that cancer is not incurable.
Early symptoms
1, Although some patients with early breast cancer have not been able to touch a clear mass in the breast department. but often feel discomfort in the Parts of the body, Especially postmenopausal women. Sometimes feel slight pain discomfort in the side of the breast, Soreness, Even in the side of the upper arm.
2, Lump can be felt by hand in the breast, It is hard, movable in early stages. Generally there is no considerable pain, a small number of Paroxysmal pain, dull pain or tingling.
3, changes in breast appearance: Visible tumor at the skin bulge, Some of the local orange peel-like, Or edema, discoloration, eczema-like changes and so on.
4, With nipple retraction near the center of the nipple.
5, nipple discharge: If the discharge was bloody, bloody serous should pay special attention for further examination.
6, Local lymph node enlargement, axillary lymph nodes is the most common on the same side. Lymph nodes in the supraclavicular were already late.
Subscribe to:
Posts (Atom)